Welcome to the e-CCO Library!

OP36 Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Giri1,2, K. Shamsunnahar3, A. Salim3, R. Capon3, M. Morrison4, P. O Cuiv4, J. Begun1,2

Created: Thursday, 30 January 2020, 10:12 AM
OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Sato*1, K. Li1, K. Hayden1, L. Tomsho1, F. Baribaud1, C. Brodmerkel1, L. E. Greenbaum1, J. R. Friedman1, M. Curran1, Y. Imai2, S. Plevy1, S. E. Telesco1

Created: Friday, 22 February 2019, 9:41 AM
OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
Year: 2022
Source: ECCO'22
Authors: Sands, B.E.(1);Feagan, B.G.(2);Sandborn, W.J.(3);Shipitofsky, N.(4);Marko, M.(4);Sheng, S.(4);Johanns, J.(4);Germinaro, M.(4);Vetter, M.(4);Panés, J.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP36: Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Deppe, H.(4);Mohl, W.(5);Teich, N.(6);Hoffstadt, M.(7);Schweitzer, A.(8);von der Ohe, M.(9);Gauss, A.(10);Atreya, R.(11);Krause, T.(12);Blumenstein, I.(13);Fajardo Salmon, S.(3);Hartmann, P.(4);Gilman, E.(3);Schreiber, S.(3,14);
Created: Friday, 14 July 2023, 10:43 AM
OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Bossuyt, P.(1);Ferrante, M.(2);Baert, F.(3);Danese, S.(4);Feagan, B.G.(5);Loftus Jr, E.V.(6);Panés, J.(7);Peyrin-Biroulet, L.(8);Ran, Z.(9);Armuzzi, A.(10);D’Haens, G.R.(11);SONG, A.(12);Neimark, E.(12);Liao, X.(12);Zhou, Q.(12);Berg, S.(12);Wallace, K.(12);Panaccione, R.(13)
Created: Wednesday, 2 June 2021, 4:12 PM
OP37 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Creyns1,2, J. Cremer1,2, G. De Hertogh3, L. Boon4, M. Ferrante2,5, S. Vermeire2,5, G. Van Assche2,5, J. Ceuppens1, C. Breynaert1,6, Allergy and Clinical Immunology Research Group

Created: Thursday, 30 January 2020, 10:12 AM
OP37: Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells
Year: 2022
Source: ECCO'22
Authors: Mathew, L.(1);Savage, M.(1);Pardieu, C.(1);O'Brien, M.(1);Sze, S.K.(2);Eberl, M.(3);Stagg, A.(1);Gasparetto, M.(4);Kok, K.(4);Lindsay, J.(4);McCarthy, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, B. E. Sands2, R. Panaccione3, C. D. O’Brien4, H. Zhang4, J. Johanns4, L. Peyrin-Biroulet5, G. Van Assche6, S. Danese7, S. R. Targan8, M. T. Abreu9, T. Hisamatsu10, P. Szapary4, C. Marano4

Created: Friday, 22 February 2019, 9:41 AM
OP37: Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chaparro, M.(1)*;García Donday, M.(1);Riestra, S.(2);Lucendo, A.J.(3);Benítez, J.M.(4);Navarro-Llavat, M.(5);Barrio, J.(6);Morales-Alvarado, V.J.(7);Rivero, M.(8);Busquets, D.(9);Leo Carnerero, E.(10);Merino Ochoa, O.(11);Nantes Castillejo, O.(12);Navarro, P.(13);Van Domselaar, M.(14);Gutiérrez Casbas, A.(15);Alonso-Abreu, I.(16);Mejuto, R.(17);Fernández Salazar, L.(18);Iborra, M.(19); Martín-Arranz, M.D.(20); Pineda, J.R.(21); Sampedro, M.J.(22);Serra Nilsson, K.(23);Bouhmidi Assakali, A.(24);Batista, L.(25);Muñoz Villafranca, C.(26);Rodríguez-Lago, I.(27); Ceballos Santos, D.S.(28);Guerra, I.(29);Mañosa, M.(30);Marín Jimenez, I.(31); Vera Mendoza, I.(32);Barreiro-de Acosta, M.(17);Domènech, E.(30);Esteve, M.(25);García-Sánchez, V.(4);Nos, P.(19);Panés, J.(33);Gisbert, J.P.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Hibi, T.(2);Ritter, T.E.(3);Dinoso, J.B.(4);Hsieh, J.(4);Yun, C.(4);Zhang, J.(4);Zhao, S.(4);Loftus Jr, E.V.(5);Rogler, G.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
OP38 Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn’s disease: A multicentre randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Jongsma MSc1, M. Aardoom1, M. Cozijnsen1, M. van Pieterson1, T. de Meij2, O. Norbruis3, M. Groeneweg4, V. Wolters5, H. van Wering6, I. Hojsak7, K.L. Kolho8, T. Hummel9, J. Stapelbroek10, C. van der Feen11, P. Rheenen12, M. van Wijk2, S. Teklenburg-Roord3, J. Escher1, J. Samsom13, L. Ridder1

Created: Thursday, 30 January 2020, 10:12 AM
OP38: Developing a Cost-Effective Genomic Biomarker of Cancer Risk in Patients with Ulcerative Colitis using Low-Pass Whole Genome Sequencing of Unselected Endoscopic Biopsies: A Case-Control Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Al Bakir, I.(1);Curtius, K.(1);Smith, K.(1);Kopczynska, M.(1);Moorghen, M.(2);Hart, A.(3);Graham, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Geert. R. D’Haens*1, W. J. Sandborn2, M. Ferrante3, B. R. Bhandari4, E. Berliba5, T. Hibi6, J. Tuttle7, J. B. Canavan8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

Created: Friday, 22 February 2019, 9:41 AM
OP38: Modulation of the septin cytoskeleton ameliorates intestinal fibrogenesis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Naydenov, N.(1);Le, T.H.N.(1);Lechuga Villarauz, S.(1);Elias, M.(1);West, G.(1);Czarnecki, D.(1);Plesec, T.(1);Ivanov, A.(1);Rieder, F.(2)*;
Created: Friday, 14 July 2023, 10:43 AM
OP38: Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials
Year: 2022
Source: ECCO'22
Authors: Sandborn, W.J.(1);D'Haens, G.R.(2);Sands, B.E.(3);Panaccione, R.(4);Ng, S.C.(5);Lawendy, N.(6);Kulisek, N.(6);Guo, X.(6);Mundayat, R.(7);Su, C.(7);Panés, J.(8);
Created: Friday, 11 February 2022, 3:52 PM
OP39 Treatment of ulcerative colitis With AMT-101, a novel oral interleukin-10 immunomodulatory fusion biologic that traffics across the intestinal epithelium
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Mrsny1, B. Kanwar2, T. Mahmood3

Created: Thursday, 30 January 2020, 10:12 AM
OP39: Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ghosh, S.(1)*;Feagan, B.(2);Ott, E.(3);Gasink, C.(3);Marano, C.(4);Miao, Y.(4);Sandborn, W.(5);Danese, S.(6);Abreu, M.(7);Sands, B.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP39: Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Colombel, J.F.(2);Louis, E.(3);Ferrante, M.(4);Motoya, S.(5);Panaccione, R.(6);Torres, J.(7);Ungaro, R.C.(2);Kligys, K.(8);Kalabic, J.(9);Zambrano, J.(8);Zhang, Y.(8);D’Haens, G.R.(10);
Created: Friday, 11 February 2022, 3:52 PM
OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Bourgonje, A.R.(1);Hu, S.(1);Spekhorst, L.M.(1);Zhernakova, D.V.(2);Vich Vila, A.(1);Li, Y.(1);Voskuil, M.D.(1);van Berkel, L.A.(3);Bley Folly, B.(3);Charrout, M.(4);Mahfouz, A.(4);Reinders, M.J.T.(4);van Heck, J.I.P.(5);Joosten, L.A.B.(5);Visschedijk, M.C.(1);van Dullemen, H.M.(1);Faber, K.N.(1);Samsom, J.N.(3);Festen, E.A.M.(1);Dijkstra, G.(1);Weersma, R.K.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP40 A core transferable microbiota in responders to faecal microbiota transplant for ulcerative colitis shape mucosal T-cell immunity
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Gogokhia1, S. Lima1, M. Viladomiu1, Y. Gerardin2, C. Crawford1, V. Jacob1, E. Scherl1, M. Rosenthal3, S.E. Brown3, J. Hambor3, R. LONGMAN1

Created: Thursday, 30 January 2020, 10:12 AM